Skip to main content
OpenTrials

Clinical trial condition

Neuroendocrine Tumors

Explore clinical trials studying Neuroendocrine Tumors. Study availability and eligibility vary by location and protocol.

387 public trials 106 recruiting studies
Refine in advanced search Browse all conditions

Neuroendocrine Tumors trial results

Completed

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

NCT05017662

Conditions
Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +3 more
Locations
  • Peter Maccallum Cancer Center Melbourne, Australia
  • Ramsay Hollywood Private Hospital Perth, Australia
  • Medical University of Vienna Vienna, Austria
  • Aarhus University Hospital Aarhus, Denmark
View Trial Details
Completed

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

NCT02611024

Conditions
Adenoma, Adnexal Diseases, Advanced Solid Tumors, +53 more
Locations
  • Sarcoma Oncology Center Santa Monica, California, United States
  • Massachusetts General Hospital - Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View all 23 locations
View Trial Details
Completed

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

NCT02279433

Conditions
Colonic Diseases, Colorectal Neoplasms, Digestive System Diseases, +23 more
Locations
  • HonorHealth Research Institute Scottsdale, Arizona, United States
  • Chao Family Comprehensive Cancer Center of Orange, California, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Inst. Boston, Massachusetts, United States
View Trial Details
Completed

Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study

NCT04400474

Conditions
Adenocarcinoma, Anaplastic Thyroid Cancer, Carcinoma, +11 more
Locations
  • Hospital Germans Trias i Pujol - ICO Badalona Badalona, Barcelona, Spain
  • Hospital Duran i Reynals - ICO L'Hospitalet L'Hospitalet de Llobregat, Barcelona, Spain
  • Hospital General Universitario Elche Alicante, Spain
  • Hospital Universitari Vall d'Hebron Barcelona, Spain
View all 15 locations
View Trial Details
Completed

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

NCT03037385

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Bronchial Diseases, +55 more
Locations
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • UC Irvine Medical Center Orange, California, United States
  • University of Colorado Anschutz Medical Campus Aurora, Colorado, United States
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
View all 71 locations
View Trial Details

Related conditions